180 related articles for article (PubMed ID: 14665873)
1. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Stephan C; Yousef GM; Scorilas A; Jung K; Jung M; Kristiansen G; Hauptmann S; Kishi T; Nakamura T; Loening SA; Diamandis EP
J Urol; 2004 Jan; 171(1):187-91. PubMed ID: 14665873
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
Yousef GM; Stephan C; Scorilas A; Ellatif MA; Jung K; Kristiansen G; Jung M; Polymeris ME; Diamandis EP
Prostate; 2003 Sep; 56(4):287-92. PubMed ID: 12858357
[TBL] [Abstract][Full Text] [Related]
3. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Chen Z; Fan Z; McNeal JE; Nolley R; Caldwell MC; Mahadevappa M; Zhang Z; Warrington JA; Stamey TA
J Urol; 2003 Apr; 169(4):1316-9. PubMed ID: 12629351
[TBL] [Abstract][Full Text] [Related]
4. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
5. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
6. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
[TBL] [Abstract][Full Text] [Related]
7. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Lucas JM; True L; Hawley S; Matsumura M; Morrissey C; Vessella R; Nelson PS
J Pathol; 2008 Jun; 215(2):118-25. PubMed ID: 18338334
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
Stephan C; Yousef GM; Scorilas A; Jung K; Jung M; Kristiansen G; Hauptmann S; Bharaj BS; Nakamura T; Loening SA; Diamandis E
J Urol; 2003 Jan; 169(1):361-4. PubMed ID: 12478190
[TBL] [Abstract][Full Text] [Related]
9. Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer.
Sidiropoulos M; Chang A; Jung K; Diamandis EP
Br J Cancer; 2001 Aug; 85(3):393-7. PubMed ID: 11487271
[TBL] [Abstract][Full Text] [Related]
10. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.
Kishi H; Igawa M; Kikuno N; Yoshino T; Urakami S; Shiina H
J Urol; 2004 May; 171(5):1855-60. PubMed ID: 15076293
[TBL] [Abstract][Full Text] [Related]
11. Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma.
Väre P; Loikkanen I; Hirvikoski P; Vaarala MH; Soini Y
Oncol Rep; 2008 Jan; 19(1):25-31. PubMed ID: 18097572
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling reveals hepsin overexpression in prostate cancer.
Magee JA; Araki T; Patil S; Ehrig T; True L; Humphrey PA; Catalona WJ; Watson MA; Milbrandt J
Cancer Res; 2001 Aug; 61(15):5692-6. PubMed ID: 11479199
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
14. Expression of ezrin in prostatic intraepithelial neoplasia.
Pang ST; Fang X; Valdman A; Norstedt G; Pousette A; Egevad L; Ekman P
Urology; 2004 Mar; 63(3):609-12. PubMed ID: 15028477
[TBL] [Abstract][Full Text] [Related]
15. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of BMP7 in human colorectal cancer.
Motoyama K; Tanaka F; Kosaka Y; Mimori K; Uetake H; Inoue H; Sugihara K; Mori M
Ann Surg Oncol; 2008 May; 15(5):1530-7. PubMed ID: 18259822
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
Arencibia JM; Martín S; Pérez-Rodríguez FJ; Bonnin A
Int J Oncol; 2009 Feb; 34(2):457-63. PubMed ID: 19148481
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
Halvorsen OJ; Oyan AM; Bø TH; Olsen S; Rostad K; Haukaas SA; Bakke AM; Marzolf B; Dimitrov K; Stordrange L; Lin B; Jonassen I; Hood L; Akslen LA; Kalland KH
Int J Oncol; 2005 Feb; 26(2):329-36. PubMed ID: 15645116
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
20. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
